What Is Amylin?

1. What Is Amylin?

Amylin is a hormone made by pancreatic beta cells. The current DailyMed Symlin label states amylin is colocated with insulin in secretory granules and cosecreted with insulin in response to food intake. The same label describes pramlintide, Symlin’s active ingredient, as an analog of human amylin.

In short, amylin is part of the body’s meal-response system.

That meal-response role matters because amylin affects gastric emptying, post-meal glucagon, post-meal glucose appearance, and appetite.

Common terminology includes:

For the GLP-1 side of the map, see What Is a GLP-1?. For the approved amylin analog brand context, see What Is Symlin?.

2. Is Amylin the Same as IAPP?

Yes. IAPP means islet amyloid polypeptide. A PubMed-indexed review describes IAPP, also called amylin, as a 37-amino-acid peptide produced by islet beta cells and cosecreted with insulin. Most patient-facing articles use “amylin,” while many physiology papers use “IAPP.”

The IAPP name points to amyloid deposits in pancreatic islets, a research area tied to type 2 diabetes biology. “Amylin” is generally used for hormone and drug-class education, while “IAPP” is more common when discussing peptide structure, beta-cell biology, or amyloid deposits.

3. What Does Amylin Do After Meals?

DailyMed and Endotext describe the same broad pattern: amylin slows gastric emptying, suppresses meal-related glucagon, and affects satiety through brain-mediated pathways. Endotext also notes that amylin secretion in response to nutrients is absent in type 1 diabetes and impaired in type 2 diabetes.

The meal-related sequence is generally:

Insulin handles glucose uptake and storage, while amylin helps shape the post-meal curve. Many people with diabetes learn insulin vocabulary early and amylin vocabulary much later, if at all. When obesity-drug news mentions an “amylin analogue,” the term can feel new, even though the hormone is not. The commercial interest around longer-acting amylin biology is what has changed.

4. Is Amylin a GLP-1?

No. Amylin is not GLP-1, and an amylin analog is not a GLP-1 receptor agonist. GLP-1 receptor agonists include names such as semaglutide and liraglutide. Amylin analog wording belongs to pramlintide and cagrilintide.

This distinction is important because some newer products and trial programs combine pathways. Novo Nordisk describes CagriSema as a fixed-dose combination of cagrilintide 2.4 mg (a long-acting amylin analogue) and semaglutide 2.4 mg (a GLP-1 receptor agonist). Novo also describes amycretin, now called zenagamtide in its 2025 annual report, as a unimolecular long-acting GLP-1 and amylin receptor agonist.

Understanding which molecule is doing what is essential:

5. What Is Pramlintide?

Pramlintide acetate is a synthetic analog of human amylin. The DailyMed label identifies Symlin as an amylin analog for patients with type 1 or type 2 diabetes who use mealtime insulin and have not reached desired glycemic control despite optimal insulin therapy.

The labeling includes strict safety parameters. Symlin carries a boxed warning because use with insulin increases the risk of severe hypoglycemia, especially in type 1 diabetes. DailyMed says severe hypoglycemia, when it occurs, is usually seen within 3 hours after a Symlin injection.

Pramlintide is not an insulin replacement, a GLP-1, or an over-the-counter appetite suppressant. It is prescribed alongside mealtime insulin and requires careful dose adjustment and glucose monitoring.

As of the openFDA shortage data checked on May 6, 2026, SymlinPen 60 and SymlinPen 120 are listed with a discontinued date of October 27, 2025 and related information describing discontinuation of manufacture.

6. Why Is Amylin Showing Up in Obesity Research?

Amylin affects satiety and food intake in addition to post-meal glucose signaling. That makes the pathway attractive for obesity research, especially beside semaglutide and tirzepatide.

Cagrilintide is Novo’s long-acting amylin analogue. In CagriSema, cagrilintide is combined with semaglutide, and Novo submitted a U.S. FDA application for that fixed-dose combination on December 18, 2025. Novo’s submission release says CagriSema is not approved in the U.S. or EU.

Amycretin is a different formulation. Novo’s ADA 2025 Science Hub material describes amycretin as a novel unimolecular GLP-1 and amylin receptor agonist in a phase 1b/2a trial context. Novo’s 2025 annual report later refers to zenagamtide, formerly known as amycretin, as a unimolecular long-acting GLP-1 and amylin receptor agonist, with phase 3 for weight management underway in the first quarter of 2026.

7. What Belongs in Notes?

The term “amylin” can mean a natural hormone, a class concept, an older approved analog, or a newer investigational pathway. These concepts are not interchangeable.

Key distinctions include:

8. What Is the Main Takeaway?

Amylin is the natural beta-cell hormone also called IAPP. It is released with insulin after food intake and is tied to gastric emptying, meal-related glucagon, satiety, and post-meal glucose patterns.

In medication contexts, pramlintide is the older FDA-labeled amylin analog tied to Symlin. Cagrilintide is Novo’s investigational long-acting amylin analogue. CagriSema combines cagrilintide with semaglutide, and Amycretin (zenagamtide) is a GLP-1 and amylin receptor agonist program.

To understand amylin treatments and research, always separate the hormone, the molecule, the product name, and the regulatory status.

9. What Is Amylin FAQ

• What is amylin in simple terms?

  Amylin is a hormone made by pancreatic beta cells and released with insulin after food intake. It is also called islet amyloid polypeptide, or IAPP. Public drug discussions usually mention amylin because pramlintide, cagrilintide, CagriSema, and amycretin all touch this pathway in different ways.

• Is amylin the same as IAPP?

  Yes. IAPP means islet amyloid polypeptide. In diabetes and obesity writing, amylin and IAPP usually refer to the same natural 37-amino-acid peptide hormone.

• Is amylin a GLP-1?

  No. Amylin and GLP-1 are separate hormone systems. GLP-1 receptor agonists include drugs such as semaglutide and liraglutide. Amylin analog wording is used for pramlintide and cagrilintide.

• Is amylin FDA-approved?

  Natural amylin is a hormone, not a drug approval. Pramlintide acetate, an amylin analog sold as Symlin or SymlinPen, has FDA labeling for defined insulin-treated diabetes use. Newer amylin-related obesity drugs are separate development programs.

• Why do people mention amylin with weight-loss drugs?

  Amylin affects appetite, satiety, gastric emptying, and meal-related glucagon signaling. That makes amylin analogs and amylin receptor agonists relevant to newer obesity research, including cagrilintide, CagriSema, and amycretin.

10. Sources